Category: Medical
CHOP Research Reveals New Target for Crohn’s Treatment
Researchers at Children’s Hospital of Philadelphia have identified unique pro-inflammatory epithelial cells in pediatric Crohn’s patients, offering new hope for more targeted treatments. This cellular-level discovery could lead to therapies that address specific inflammatory pathways rather than suppressing the entire immune system.
Your Doctor Just Mentioned Biologics: What’s Next on Your IBD Journey
When your doctor suggests biologic treatment for Crohn’s disease, it can feel both hopeful and overwhelming. Here’s what this important decision means for your IBD journey and how to approach it with confidence.
AI Breakthrough Could Fast-Track Life-Changing IBD Treatments
A groundbreaking AI platform has successfully demonstrated the ability to generate regulatory-grade real-world data, potentially accelerating the approval process for new IBD treatments. This breakthrough could significantly reduce the time it takes for life-changing therapies to reach patients who need them most.
New Treatment Shows Promise for Severe Crohn’s Complications
Palisade Bio has begun dosing patients in a groundbreaking clinical trial for fibrostenotic Crohn’s disease, testing a treatment that could prevent intestinal scarring rather than just managing it after it occurs. This represents new hope for patients facing one of Crohn’s most challenging complications.
Beyond Bloating: Practical Ways to Find Relief with Crohn’s
Crohn’s bloating isn’t just discomfort—it’s a complex symptom that affects confidence and daily life. New guidance reveals practical strategies for identifying triggers and finding relief through systematic tracking, lifestyle modifications, and careful communication with your healthcare team.
New Treatment Hope for Fibrostenotic Crohn’s: First Human Trial
Palisade Bio has begun the first human trial of PALI-2108, a new oral treatment specifically designed for fibrostenotic Crohn’s disease that targets scarring rather than just inflammation. This represents a potentially groundbreaking approach for patients whose Crohn’s has progressed to cause intestinal narrowing and strictures.
New Gut Healing Drug Shows Promise for IBD Patients
Palisade Bio has begun testing PALI-2108, a new oral drug designed to repair damaged intestinal barriers in IBD patients. While still in early-stage trials, this approach targets the root cause of gut dysfunction rather than just managing symptoms.
Hope on the Horizon: FDA Approves New IBD Treatment Option
The FDA has approved upadacitinib (Rinvoq) for adults with moderately to severely active Crohn’s disease and ulcerative colitis. This JAK inhibitor offers new hope for IBD patients seeking better symptom control, especially those who haven’t found success with conventional treatments.
The Stress-IBD Connection: What Every Patient Should Know
New expert insights clarify the complex relationship between stress and IBD, explaining how stress can worsen symptoms without actually causing the condition. This understanding has important implications for both diagnosis and treatment approaches.
New Gut-Brain Research Offers Hope for IBD Treatment Advances
New research from Boston Children’s Hospital identifies proteins that explain gut-brain connections in IBD. This breakthrough could lead to more comprehensive treatments addressing both physical and emotional aspects of Crohn’s disease and ulcerative colitis.
